Zacks Investment Research upgraded shares of EXELIXIS INC (EXEL) from NEUTRAL to OUTPERFORM on October 09, 2012, with a target price of $5.70.
Exelixis Inc. is a leader in the fields of model system genetics and comparative genomics. These fields involve the systematic study of simple organisms, such as fruit flies, nematodes, mice, zebrafish and simple plants, to rapidly and efficiently determine gene function and establish its commercial utility in humans and other commercially important biological systems. The proprietary technologies provide a rapid, efficient and cost-effective way to move beyond DNA sequence data to understand the function of genes and the proteins that they encode.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on EXELIXIS INC (EXEL),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment